BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Concentrations

Concentrations

12 Months Ended

Dec. 31, 2021

Risks And Uncertainties [Abstract]

Concentrations

NOTE 10 — CONCENTRATIONS

Revenue from the Company’s products are as follows ($ in thousands):


	Years Ended December 31,
	2021				2020				2019
Laser systems	$	25,023	63.9	%	$	12,342	54.2	%	$	22,842	60.4	%
Imaging systems		—	—			—	—			619	1.6	%
Consumables and other		9,456	24.1	%		6,124	26.9	%		7,164	19.0	%
Services		4,709	12.0	%		4,314	18.9	%		7,162	19.0	%
License fees and royalties		—	—			—	—			12	—
Total revenue	$	39,188	100	%	$	22,780	100.0	%	$	37,799	100.0	%

The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

For the years ended December 31, 2021, 2020, and 2019, sales to our largest distributor worldwide accounted for approximately 5%, 5%, and 4%, respectively, of our net revenue. No individual customer represented more than 10% of the Company’s accounts receivable at December 31, 2021 and 2020.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations and financial condition.